Erin E Fox1, John B Holcomb, Charles E Wade, Eileen M Bulger, Barbara C Tilley. 1. *Center for Translational Injury Research, Division of Acute Care Surgery, Department of Surgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas †Division of Trauma and Critical Care, Department of Surgery, School of Medicine, University of Washington, Seattle, Washington ‡Division of Biostatistics, School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas.
Abstract
BACKGROUND: Choosing the appropriate endpoint for a trauma hemorrhage control trial can determine the likelihood of its success. Recent Phase 3 trials and observational studies have used 24-h and/or 30-day all-cause mortality as the primary endpoint and some have not used exception from informed consent (EFIC), resulting in multiple failed trials. Five recent high-quality prospective studies among 4,064 hemorrhaging trauma patients provide new evidence to support earlier primary endpoints. METHODS: The goal of this project was to determine the optimal endpoint for hemorrhage control trials using existing literature and new analyses of previously published data. RESULTS: Recent studies among bleeding trauma patients show that hemorrhagic deaths occur rapidly, at a high rate, and in a consistent pattern. Early preventable deaths among trauma patients are largely due to hemorrhage and the median time to hemorrhagic death from admission is 2.0 to 2.6 h. Approximately 85% of hemorrhagic deaths occur within 6 h. The hourly mortality rate due to traumatic injury decreases rapidly after enrollment from 4.6% per hour at 1 hour postenrollment to 1% per hour at 6 h to <0.1% per hour by 9 h and thereafter. Early primary endpoints (within 6 h) have critically important benefits for hemorrhage control trials, including being congruent with the median time to hemorrhagic death, biologic plausibility, and enabling the use of all-cause mortality, which is definitive and objective. CONCLUSIONS: Primary endpoints should be congruent with the timing of the disease process. Therefore, if a resuscitation/hemorrhage control intervention is under study, a primary endpoint of all-cause mortality evaluated within the first 6 h is appropriate. Before choosing the timing of the primary endpoint for a large multicenter trial, we recommend performing a Phase 2 trial under EFIC to better understand the effects of the hemorrhage control intervention and distribution of time to death. When early primary endpoints are used, patients should be monitored for multiple subsequent secondary safety endpoints, including 24 h and 30-day all-cause mortality as well as the customary safety endpoints.
BACKGROUND: Choosing the appropriate endpoint for a trauma hemorrhage control trial can determine the likelihood of its success. Recent Phase 3 trials and observational studies have used 24-h and/or 30-day all-cause mortality as the primary endpoint and some have not used exception from informed consent (EFIC), resulting in multiple failed trials. Five recent high-quality prospective studies among 4,064 hemorrhaging traumapatients provide new evidence to support earlier primary endpoints. METHODS: The goal of this project was to determine the optimal endpoint for hemorrhage control trials using existing literature and new analyses of previously published data. RESULTS: Recent studies among bleeding traumapatients show that hemorrhagic deaths occur rapidly, at a high rate, and in a consistent pattern. Early preventable deaths among traumapatients are largely due to hemorrhage and the median time to hemorrhagic death from admission is 2.0 to 2.6 h. Approximately 85% of hemorrhagic deaths occur within 6 h. The hourly mortality rate due to traumatic injury decreases rapidly after enrollment from 4.6% per hour at 1 hour postenrollment to 1% per hour at 6 h to <0.1% per hour by 9 h and thereafter. Early primary endpoints (within 6 h) have critically important benefits for hemorrhage control trials, including being congruent with the median time to hemorrhagic death, biologic plausibility, and enabling the use of all-cause mortality, which is definitive and objective. CONCLUSIONS: Primary endpoints should be congruent with the timing of the disease process. Therefore, if a resuscitation/hemorrhage control intervention is under study, a primary endpoint of all-cause mortality evaluated within the first 6 h is appropriate. Before choosing the timing of the primary endpoint for a large multicenter trial, we recommend performing a Phase 2 trial under EFIC to better understand the effects of the hemorrhage control intervention and distribution of time to death. When early primary endpoints are used, patients should be monitored for multiple subsequent secondary safety endpoints, including 24 h and 30-day all-cause mortality as well as the customary safety endpoints.
Authors: John B Holcomb; Richard Weiskopf; Howard Champion; Steven A Gould; R Michelle Sauer; Karen Brasel; Grant Bochicchio; Eileen Bulger; Bryan A Cotton; Daniel Davis; Richard Dutton; Carl J Hauser; John R Hess; George A Hides; Paula Knudson; Ellen MacKenzie; Robert L McGinnis; Joel Michalek; Frederick A Moore; Laurel Omert; Brad H Pollock; Bartholomew Tortella; Jeremy Sugarman; Martin A Schreiber; Charles E Wade Journal: Shock Date: 2011-02 Impact factor: 3.454
Authors: John B Holcomb; Barbara C Tilley; Sarah Baraniuk; Erin E Fox; Charles E Wade; Jeanette M Podbielski; Deborah J del Junco; Karen J Brasel; Eileen M Bulger; Rachael A Callcut; Mitchell Jay Cohen; Bryan A Cotton; Timothy C Fabian; Kenji Inaba; Jeffrey D Kerby; Peter Muskat; Terence O'Keeffe; Sandro Rizoli; Bryce R H Robinson; Thomas M Scalea; Martin A Schreiber; Deborah M Stein; Jordan A Weinberg; Jeannie L Callum; John R Hess; Nena Matijevic; Christopher N Miller; Jean-Francois Pittet; David B Hoyt; Gail D Pearson; Brian Leroux; Gerald van Belle Journal: JAMA Date: 2015-02-03 Impact factor: 56.272
Authors: Andrew C Bernard; Ernest E Moore; Frederick A Moore; George A Hides; Brian J Guthrie; Laurel A Omert; Steven A Gould; George H Rodman Journal: J Trauma Date: 2011-05
Authors: Eileen M Bulger; Susanne May; Jeffery D Kerby; Scott Emerson; Ian G Stiell; Martin A Schreiber; Karen J Brasel; Samuel A Tisherman; Raul Coimbra; Sandro Rizoli; Joseph P Minei; J Steven Hata; George Sopko; David C Evans; David B Hoyt Journal: Ann Surg Date: 2011-03 Impact factor: 12.969
Authors: Carl J Hauser; Kenneth Boffard; Richard Dutton; Gordon R Bernard; Martin A Croce; John B Holcomb; Ari Leppaniemi; Michael Parr; Jean-Louis Vincent; Bartholomew J Tortella; Jeannett Dimsits; Bertil Bouillon Journal: J Trauma Date: 2010-09
Authors: Zeinab M Alawadi; Eric LeFebvre; Erin E Fox; Deborah J Del Junco; Bryan A Cotton; Charles E Wade; John B Holcomb Journal: Surgery Date: 2015-05-07 Impact factor: 3.982
Authors: John B Holcomb; Deborah J del Junco; Erin E Fox; Charles E Wade; Mitchell J Cohen; Martin A Schreiber; Louis H Alarcon; Yu Bai; Karen J Brasel; Eileen M Bulger; Bryan A Cotton; Nena Matijevic; Peter Muskat; John G Myers; Herb A Phelan; Christopher E White; Jiajie Zhang; Mohammad H Rahbar Journal: JAMA Surg Date: 2013-02 Impact factor: 14.766
Authors: Rachael A Callcut; Kit N Simpson; Sarah Baraniuk; Erin E Fox; Barbara C Tilley; John B Holcomb Journal: Transfusion Date: 2020-05-01 Impact factor: 3.157
Authors: Ronald Chang; Erin E Fox; Thomas J Greene; Brian J Eastridge; Ramyar Gilani; Kevin K Chung; Stacia M DeSantis; Joseph J DuBose; Jeffrey S Tomasek; Gerald R Fortuna; Valerie G Sams; S Rob Todd; Jeanette M Podbielski; Charles E Wade; John B Holcomb Journal: J Trauma Acute Care Surg Date: 2017-07 Impact factor: 3.313
Authors: Elissa K Butler; Brianna M Mills; Saman Arbabi; Eileen M Bulger; Monica S Vavilala; Jonathan I Groner; Lynn G Stansbury; John R Hess; Frederick P Rivara Journal: Crit Care Med Date: 2019-07 Impact factor: 7.598
Authors: Ronald Chang; Jeffrey D Kerby; Kyle J Kalkwarf; Gerald Van Belle; Erin E Fox; Bryan A Cotton; Mitchell J Cohen; Martin A Schreiber; Karen Brasel; Eileen M Bulger; Kenji Inaba; Sandro Rizoli; Jeanette M Podbielski; Charles E Wade; John B Holcomb Journal: J Trauma Acute Care Surg Date: 2019-08 Impact factor: 3.313
Authors: Rachael A Callcut; Lucy Z Kornblith; Amanda S Conroy; Anamaria J Robles; Jonathan P Meizoso; Nicholas Namias; David E Meyer; Amanda Haymaker; Michael S Truitt; Vaidehi Agrawal; James M Haan; Kelly L Lightwine; John M Porter; Janika L San Roman; Walter L Biffl; Michael S Hayashi; Michael J Sise; Jayraan Badiee; Gustavo Recinos; Kenji Inaba; Thomas J Schroeppel; Emma Callaghan; Julie A Dunn; Samuel Godin; Robert C McIntyre; Erik D Peltz; Patrick J OʼNeill; Conrad F Diven; Aaron M Scifres; Emily E Switzer; Michaela A West; Sarah Storrs; Daniel C Cullinane; John F Cordova; Ernest E Moore; Hunter B Moore; Alicia R Privette; Evert A Eriksson; Mitchell Jay Cohen Journal: J Trauma Acute Care Surg Date: 2019-05 Impact factor: 3.313
Authors: Ying Chen; Zhipeng Xu; Qi Song; Zhenjie Wang; Zhong Ji; Zhaolei Qiu; Feng Cheng; Hai Jiang Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2019-10-30
Authors: Mitchell B Robinson; Anna M Wisniowiecki; Ryan J Butcher; Mark A Wilson; M Nance Ericson; Gerard L Cote Journal: J Biomed Opt Date: 2018-05 Impact factor: 3.170
Authors: Aaron R Jensen; Cory McLaughlin; Haris Subacius; Katie McAuliff; Avery B Nathens; Carolyn Wong; Daniella Meeker; Randall S Burd; Henri R Ford; Jeffrey S Upperman Journal: J Trauma Acute Care Surg Date: 2019-10 Impact factor: 3.313